Rankings
▼
Calendar
EYPT Q3 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
EYPT
EyePoint Pharmaceuticals, Inc.
$1B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$11M
-30.8% YoY
Gross Profit
$10M
93.0% margin
Operating Income
-$33M
-311.2% margin
Net Income
-$29M
-279.0% margin
EPS (Diluted)
$-0.54
QoQ Revenue Growth
+11.0%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$41M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$301M
Total Liabilities
$82M
Stockholders' Equity
$219M
Cash & Equivalents
$80M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$11M
$15M
-30.8%
Gross Profit
$10M
$14M
-30.1%
Operating Income
-$33M
-$14M
-127.4%
Net Income
-$29M
-$13M
-132.8%
Revenue Segments
License And Collaboration Agreement
$10M
85%
Y U T I Q Product
$700,000
6%
Product
$664,000
6%
Royalty
$299,000
3%
← FY 2024
All Quarters
Q4 2024 →